PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
- Posted on May 14, 2026
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the brain's connections... Read More
p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease
- Posted on May 17, 2024
The 26-week Phase 2a trial met its primary endpoint for safety and tolerability, with biomarker and imaging signals supporting further study.... Read More
Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer’s Disease and PSP
- Posted on May 7, 2026
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.... Read More
A better Alzheimer’s drug?
- Posted on Feb 25, 2026
Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.... Read More
p75 receptor modulation slows biomarkers and preserves visuospatial function
- Posted on Dec 2, 2025
CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.... Read More
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
- Posted on Apr 3, 2025
NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.... Read More
Alzheimer’s from a New Angle
- Posted on Feb 11, 2016
Dr. Frank Longo on hope, innovation, and a radical departure from traditional Alzheimer’s research... Read More
Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease
- Posted on Jul 13, 2026
New findings presented at featured research session (FRS) during the Alzheimer’s Association International Conference demonstrate statistically significant slowing of decline in brain network function with LM11A-31 vs placebo linked to cognitive domains and synaptic resilience MENLO PARK, California (July 13, 2026) – Indiana University and PharmatrophiX, a privately-held, clinical-stage biopharmaceutical company pioneering the development of ... Read More